Spesolimab - solution for infusion
1368-0104
Phase 3 small_molecule terminated
Quick answer
Spesolimab - solution for infusion for Netherton Syndrome is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Netherton Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated